MENU
+Compare
PDSB
Stock ticker: NASDAQ
AS OF
May 21 closing price
Price
$1.58
Change
-$0.05 (-3.07%)
Capitalization
72.22M

PDSB PDS Biotechnology Corp Forecast, Technical & Fundamental Analysis

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more

PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PDSB with price predictions
May 20, 2025

PDSB in upward trend: price rose above 50-day moving average on May 12, 2025

PDSB moved above its 50-day moving average on May 12, 2025 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 15, 2025. You may want to consider a long position or call options on PDSB as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PDSB just turned positive on May 12, 2025. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 133 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PDSB broke above its upper Bollinger Band on May 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.230) is normal, around the industry mean (16.528). P/E Ratio (0.000) is within average values for comparable stocks, (60.481). PDSB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.209). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (282.857).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PDSB is expected to report earnings to rise 17.48% to -24 cents per share on August 13

PDS Biotechnology Corp PDSB Stock Earnings Reports
Q2'25
Est.
$-0.25
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.10
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.10
The last earnings report on May 14 showed earnings per share of -20 cents, beating the estimate of -31 cents. With 645.25K shares outstanding, the current market capitalization sits at 72.22M.
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
25
Web
https://www.pdsbiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X109678.0800002886.992200
+2.70%
Bitcoin cryptocurrency
GME28.05-0.46
-1.61%
GameStop Corp
SPY582.86-9.99
-1.69%
SPDR® S&P 500® ETF
AAPL202.09-4.77
-2.31%
Apple
TSLA334.62-9.20
-2.68%
Tesla

PDSB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+11.64%
RXRX - PDSB
47%
Loosely correlated
+0.89%
KYMR - PDSB
47%
Loosely correlated
+4.11%
NTLA - PDSB
44%
Loosely correlated
+6.73%
ATOS - PDSB
43%
Loosely correlated
-4.22%
CRNX - PDSB
43%
Loosely correlated
+1.36%
More